Home › NCT06830629
A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
RecruitingPhase 2
An Open-Label Phase 2 Study to Evaluate the Safety, Tolerability, and Effect on Albuminuria of MZE829 in Adults With Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype
Who can join
Ages 18 to 68 · All sexes
Full eligibility criteria
Key Inclusion Criteria:
* APOL1 high risk genotype of G1/G1, G2/G2, or G1/G2
* Chronic kidney disease with persistent albuminuria
Key Exclusion Criteria:
* Organ or bone marrow transplantation
* History of active cancer within past 2 years, except for treated non-melanoma skin cancer, stage 0 cervical cancer, or stage 1 prostate cancer
* Conditions that may alter drug absorption, e.g., history of bariatric surgery
* Type I diabetes
* Pregnant or currently nursing
Other inclusion/exclusion criteria defined in protocol apply.
About the study
The purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease.
What is being tested
Sponsor: Maze Therapeutics · Participants: 74 · Started: Feb 5, 2025
Contact the study team
Official record on ClinicalTrials.gov — NCT06830629
Locations in the U.S.
| Alabama | Research Site, Decatur
Research Site, Huntsville
Research Site, Montgomery
Research Site, Montgomery |
| Connecticut | Research Site, Bloomfield |
| District of Columbia | Research Site, Washington D.C. |
| Florida | Research Site, Atlantis
Research Site, Brandon
Research Site, Hollywood
Research Site, Melbourne
Research Site, Orlando |
| Georgia | Research Site, Atlanta
Research Site, College Park
Research Site, Cordele
Research Site, Macon
Research Site, Riverdale
Research Site, Riverdale
Research Site, Savannah
Research Site, Snellville |
| Illinois | Research Site, Chicago
Research Site, Chicago
Research Site, Evanston |
| Kansas | Research Site, Kansas City |
| Kentucky | Research Site, Bowling Green
Research Site, Louisville |
| Maryland | Research Site, Arnold
Research Site, Lutherville
Research Site, Oxon Hill |
| Michigan | Research Site, Dearborn
Research Site, Flint
Research Site, Pontiac
Research Site, Saint Joseph |
| Minnesota | Research Site, Minneapolis |
| Mississippi | Research Site, Tupelo |
| Missouri | Research Site, City of Saint Peters
Research Site, St Louis |
| Nevada | Research Site, Las Vegas |
| New Jersey | Research Site, Jersey City |
| New York | Research Site, Buffalo
Research Site, Laurelton
Research Site, Maspeth
Research Site, Newburgh |
| North Carolina | Research Site, Durham
Research Site, Fayetteville
Research Site, Greensboro
Research Site, Shelby |
| Ohio | Research Site, Cleveland
Research Site, Cleveland
Research Site, Columbus |
| Oklahoma | Research Site, Ardmore |
| Pennsylvania | Research Site, Philadelphia
Research Site, Philadelphia
Research Site, Upland |
| South Carolina | Research Site, Columbia
Research Site, Spartanburg
Research Site, Spartanburg |
| Tennessee | Research Site, Chattanooga |
| Texas | Research Site, Dallas
Research Site, Dallas
Research Site, Greenville
Research Site, Houston
Research Site, Houston
Research Site, Houston
Research Site, McKinney
Research Site, San Antonio
Research Site, Shenandoah
Research Site, Sherman |
| Virginia | Research Site, Norfolk |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.